var timelineData = {
  "nodes": [
    {
      "name": "7::757382400::fbeb5d316e9452badbe8690f7b915217295e74fe::1",
      "group": 7,
      "doi": "fbeb5d316e9452badbe8690f7b915217295e74fe",
      "publication_date": 757382400,
      "path_index": 7,
      "is_original_author": "true",
      "title": "Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging.",
      "index": 0
    },
    {
      "name": "0::820454400::4e2d08257744a6635b304431adb4c2d2f3c46b16::1",
      "group": 0,
      "doi": "4e2d08257744a6635b304431adb4c2d2f3c46b16",
      "publication_date": 820454400,
      "path_index": 0,
      "is_original_author": "true",
      "title": "The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor.",
      "index": 1
    },
    {
      "name": "3::820454400::4e2d08257744a6635b304431adb4c2d2f3c46b16::1",
      "group": 3,
      "doi": "4e2d08257744a6635b304431adb4c2d2f3c46b16",
      "publication_date": 820454400,
      "path_index": 3,
      "is_original_author": "true",
      "title": "The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor.",
      "index": 2
    },
    {
      "name": "7::820454400::2c0732a9648798308c0c2ee3e89093d487f3bdbc::0",
      "group": 7,
      "doi": "2c0732a9648798308c0c2ee3e89093d487f3bdbc",
      "publication_date": 820454400,
      "path_index": 7,
      "is_original_author": "false",
      "title": "Primary staging of urinary bladder carcinoma: the role of MRI and a comparison with CT",
      "index": 3
    },
    {
      "name": "6::883612800::c611d0f3f30ff635ed69a7cfd804ab03f7953b50::1",
      "group": 6,
      "doi": "c611d0f3f30ff635ed69a7cfd804ab03f7953b50",
      "publication_date": 883612800,
      "path_index": 6,
      "is_original_author": "true",
      "title": "Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database.",
      "index": 4
    },
    {
      "name": "6::946684800::bbbce27685f31ab6934407f28e4065e05a079744::0",
      "group": 6,
      "doi": "bbbce27685f31ab6934407f28e4065e05a079744",
      "publication_date": 946684800,
      "path_index": 6,
      "is_original_author": "false",
      "title": "Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study.",
      "index": 5
    },
    {
      "name": "6::978307200::c0ee3723e0ad6d3dbeb04289e088f6ea89a1512f::0",
      "group": 6,
      "doi": "c0ee3723e0ad6d3dbeb04289e088f6ea89a1512f",
      "publication_date": 978307200,
      "path_index": 6,
      "is_original_author": "false",
      "title": "Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study.",
      "index": 6
    },
    {
      "name": "4::1009843200::3be6ccbc2e725cddedd36a45557a5dd78daf7d4b::1",
      "group": 4,
      "doi": "3be6ccbc2e725cddedd36a45557a5dd78daf7d4b",
      "publication_date": 1009843200,
      "path_index": 4,
      "is_original_author": "true",
      "title": "Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer.",
      "index": 7
    },
    {
      "name": "7::1009843200::5cb7cdc4784d390ba3d102c0cbe864de712c262d::0",
      "group": 7,
      "doi": "5cb7cdc4784d390ba3d102c0cbe864de712c262d",
      "publication_date": 1009843200,
      "path_index": 7,
      "is_original_author": "false",
      "title": "AJCC Cancer Staging Manual",
      "index": 8
    },
    {
      "name": "5::1041379200::7d35c7145568c5a621e41ce94e6958903fd2bd08::1",
      "group": 5,
      "doi": "7d35c7145568c5a621e41ce94e6958903fd2bd08",
      "publication_date": 1041379200,
      "path_index": 5,
      "is_original_author": "true",
      "title": "National practice patterns and time trends in androgen ablation for localized prostate cancer.",
      "index": 9
    },
    {
      "name": "2::1072915200::fd2d2948831a8995679a781903d4f8e2038cce89::1",
      "group": 2,
      "doi": "fd2d2948831a8995679a781903d4f8e2038cce89",
      "publication_date": 1072915200,
      "path_index": 2,
      "is_original_author": "true",
      "title": "The changing face of low-risk prostate cancer: trends in clinical presentation and primary management.",
      "index": 10
    },
    {
      "name": "1::1104537600::e2dd59400d00756b42a56bc5a6c09d40558720a2::1",
      "group": 1,
      "doi": "e2dd59400d00756b42a56bc5a6c09d40558720a2",
      "publication_date": 1104537600,
      "path_index": 1,
      "is_original_author": "true",
      "title": "Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE).",
      "index": 11
    },
    {
      "name": "2::1104537600::faf5a0517b9c44822a54ce1889c9384da7c00304::0",
      "group": 2,
      "doi": "faf5a0517b9c44822a54ce1889c9384da7c00304",
      "publication_date": 1104537600,
      "path_index": 2,
      "is_original_author": "false",
      "title": "Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy.",
      "index": 12
    },
    {
      "name": "3::1104537600::512e8a614a48a8c107f3c6ba594e8b4aab9e3ddb::0",
      "group": 3,
      "doi": "512e8a614a48a8c107f3c6ba594e8b4aab9e3ddb",
      "publication_date": 1104537600,
      "path_index": 3,
      "is_original_author": "false",
      "title": "Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma.",
      "index": 13
    },
    {
      "name": "4::1104537600::512e8a614a48a8c107f3c6ba594e8b4aab9e3ddb::0",
      "group": 4,
      "doi": "512e8a614a48a8c107f3c6ba594e8b4aab9e3ddb",
      "publication_date": 1104537600,
      "path_index": 4,
      "is_original_author": "false",
      "title": "Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma.",
      "index": 14
    },
    {
      "name": "5::1104537600::512e8a614a48a8c107f3c6ba594e8b4aab9e3ddb::0",
      "group": 5,
      "doi": "512e8a614a48a8c107f3c6ba594e8b4aab9e3ddb",
      "publication_date": 1104537600,
      "path_index": 5,
      "is_original_author": "false",
      "title": "Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma.",
      "index": 15
    },
    {
      "name": "6::1104537600::512e8a614a48a8c107f3c6ba594e8b4aab9e3ddb::0",
      "group": 6,
      "doi": "512e8a614a48a8c107f3c6ba594e8b4aab9e3ddb",
      "publication_date": 1104537600,
      "path_index": 6,
      "is_original_author": "false",
      "title": "Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma.",
      "index": 16
    },
    {
      "name": "7::1104537600::512e8a614a48a8c107f3c6ba594e8b4aab9e3ddb::0",
      "group": 7,
      "doi": "512e8a614a48a8c107f3c6ba594e8b4aab9e3ddb",
      "publication_date": 1104537600,
      "path_index": 7,
      "is_original_author": "false",
      "title": "Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma.",
      "index": 17
    },
    {
      "name": "0::1167609600::7ba400225356a7d389f04e13e2d2506f40774fc8::1",
      "group": 0,
      "doi": "7ba400225356a7d389f04e13e2d2506f40774fc8",
      "publication_date": 1167609600,
      "path_index": 0,
      "is_original_author": "true",
      "title": "Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.",
      "index": 18
    },
    {
      "name": "1::1167609600::7ba400225356a7d389f04e13e2d2506f40774fc8::1",
      "group": 1,
      "doi": "7ba400225356a7d389f04e13e2d2506f40774fc8",
      "publication_date": 1167609600,
      "path_index": 1,
      "is_original_author": "true",
      "title": "Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.",
      "index": 19
    },
    {
      "name": "2::1167609600::7ba400225356a7d389f04e13e2d2506f40774fc8::1",
      "group": 2,
      "doi": "7ba400225356a7d389f04e13e2d2506f40774fc8",
      "publication_date": 1167609600,
      "path_index": 2,
      "is_original_author": "true",
      "title": "Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.",
      "index": 20
    },
    {
      "name": "3::1167609600::7ba400225356a7d389f04e13e2d2506f40774fc8::1",
      "group": 3,
      "doi": "7ba400225356a7d389f04e13e2d2506f40774fc8",
      "publication_date": 1167609600,
      "path_index": 3,
      "is_original_author": "true",
      "title": "Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.",
      "index": 21
    },
    {
      "name": "4::1167609600::7ba400225356a7d389f04e13e2d2506f40774fc8::1",
      "group": 4,
      "doi": "7ba400225356a7d389f04e13e2d2506f40774fc8",
      "publication_date": 1167609600,
      "path_index": 4,
      "is_original_author": "true",
      "title": "Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.",
      "index": 22
    },
    {
      "name": "5::1167609600::7ba400225356a7d389f04e13e2d2506f40774fc8::1",
      "group": 5,
      "doi": "7ba400225356a7d389f04e13e2d2506f40774fc8",
      "publication_date": 1167609600,
      "path_index": 5,
      "is_original_author": "true",
      "title": "Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.",
      "index": 23
    },
    {
      "name": "6::1167609600::7ba400225356a7d389f04e13e2d2506f40774fc8::1",
      "group": 6,
      "doi": "7ba400225356a7d389f04e13e2d2506f40774fc8",
      "publication_date": 1167609600,
      "path_index": 6,
      "is_original_author": "true",
      "title": "Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.",
      "index": 24
    },
    {
      "name": "7::1167609600::7ba400225356a7d389f04e13e2d2506f40774fc8::1",
      "group": 7,
      "doi": "7ba400225356a7d389f04e13e2d2506f40774fc8",
      "publication_date": 1167609600,
      "path_index": 7,
      "is_original_author": "true",
      "title": "Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.",
      "index": 25
    }
  ],
  "links": [
    {
      "source": 18,
      "target": 1,
      "value": 1,
      "index": 0
    },
    {
      "source": 19,
      "target": 11,
      "value": 1,
      "index": 1
    },
    {
      "source": 20,
      "target": 12,
      "value": 1,
      "index": 2
    },
    {
      "source": 12,
      "target": 10,
      "value": 1,
      "index": 3
    },
    {
      "source": 21,
      "target": 13,
      "value": 1,
      "index": 4
    },
    {
      "source": 13,
      "target": 2,
      "value": 1,
      "index": 5
    },
    {
      "source": 22,
      "target": 14,
      "value": 1,
      "index": 6
    },
    {
      "source": 14,
      "target": 7,
      "value": 1,
      "index": 7
    },
    {
      "source": 23,
      "target": 15,
      "value": 1,
      "index": 8
    },
    {
      "source": 15,
      "target": 9,
      "value": 1,
      "index": 9
    },
    {
      "source": 24,
      "target": 16,
      "value": 1,
      "index": 10
    },
    {
      "source": 16,
      "target": 6,
      "value": 1,
      "index": 11
    },
    {
      "source": 6,
      "target": 5,
      "value": 1,
      "index": 12
    },
    {
      "source": 5,
      "target": 4,
      "value": 1,
      "index": 13
    },
    {
      "source": 25,
      "target": 17,
      "value": 1,
      "index": 14
    },
    {
      "source": 17,
      "target": 8,
      "value": 1,
      "index": 15
    },
    {
      "source": 8,
      "target": 3,
      "value": 1,
      "index": 16
    },
    {
      "source": 3,
      "target": 0,
      "value": 1,
      "index": 17
    }
  ]
}